MedTrace Logo

Efficacy of Tranexamic Acid (TXA) in Humerus ORIF

NCT05802238 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-13

No results posted yet for this study

Summary

The purpose of this study is to determine if administration of tranexamic acid (TXA), a clotting agent, will decrease blood loss, the need for transfusion, and reduce the likelihood of wound complications such as infection. Investigators will also see if the drug can effectively decrease operative time and length of hospitalization.

Conditions

  • Fracture Humerus

Interventions

DRUG

Tranexamic acid (TXA)

1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery

OTHER

Saline

control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.

Sponsors & Collaborators

  • Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

    lead OTHER

Principal Investigators

  • Peter Tang, MD · Allegheny Health Network Allegheny General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2024-11-25
Completion
2024-11-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05802238 on ClinicalTrials.gov